Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy
BACKGROUNDHypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development of HCM. The objectives were to determine plasma protein...
Gespeichert in:
| Veröffentlicht in: | Circulation. Heart failure 2021-07, Vol.14 (7), p.e007849-e007849 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e007849 |
|---|---|
| container_issue | 7 |
| container_start_page | e007849 |
| container_title | Circulation. Heart failure |
| container_volume | 14 |
| creator | Shimada, Yuichi J. Raita, Yoshihiko Liang, Lusha W. Maurer, Mathew S. Hasegawa, Kohei Fifer, Michael A. Reilly, Muredach P. |
| description | BACKGROUNDHypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development of HCM. The objectives were to determine plasma protein biomarkers of HCM and to reveal molecular pathways differentially regulated in HCM. METHODSWe conducted a multicenter case-control study of cases with HCM and controls with hypertensive left ventricular hypertrophy. We performed plasma proteomics profiling of 1681 proteins. We performed a sparse partial least squares discriminant analysis to develop a proteomics-based discrimination model with data from 1 institution (ie, the training set). We tested the discriminative ability in independent samples from the other institution (ie, the test set). As an exploratory analysis, we executed pathway analysis of significantly dysregulated proteins. Pathways with false discovery rate |
| doi_str_mv | 10.1161/CIRCHEARTFAILURE.120.007849 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8292216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2547531935</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4515-c9733e170934cfcb77382c23509ae69fc7999ad66ccfecda3995c37a9b6c4ca73</originalsourceid><addsrcrecordid>eNpdUV1r20AQFKGlSdP-B0Ff-iL3PnVeCgFXOLXB0GKS5-v5vIoukXTqneTgf98zDiXtw7LLzs7sspNlnyiZUVrSL9V6W62Wi-3d7WK9ud8uZ5SRGSFqLuAiu6IgaMEZqDev6svsfYyPhJRMSniXXXJBgc0BrrJfle-GgA320R0w_xn8iL5zNp7K2rWuf8i3eEDTxrxywU6tGU-9b853JjxhiLmv89VxwDAGPzTO5pUJ-4Qe_WDG5vghe1snMn58ydfZ_e3yrloVmx_f19ViU1ghqSwsKM6RKgJc2NrulOJzZhmXBAyWUFsFAGZfltbWaPeGA0jLlYFdaYU1il9nN2fdYdp1uLfYj8G0eggu3XnU3jj9L9K7Rj_4g54zYIyWSeDzi0DwvyeMo-5ctNi2pkc_Rc2kUJJT4DKNfj2P2uBjDFj_XUOJPnmk__dIJ4_02aPEFmf2s2_H9MCndnrGoJv047HRhHKuBIiCEUaJIoQUKYjkfwCKjZkc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547531935</pqid></control><display><type>article</type><title>Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy</title><source>American Heart Association Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Shimada, Yuichi J. ; Raita, Yoshihiko ; Liang, Lusha W. ; Maurer, Mathew S. ; Hasegawa, Kohei ; Fifer, Michael A. ; Reilly, Muredach P.</creator><creatorcontrib>Shimada, Yuichi J. ; Raita, Yoshihiko ; Liang, Lusha W. ; Maurer, Mathew S. ; Hasegawa, Kohei ; Fifer, Michael A. ; Reilly, Muredach P.</creatorcontrib><description>BACKGROUNDHypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development of HCM. The objectives were to determine plasma protein biomarkers of HCM and to reveal molecular pathways differentially regulated in HCM. METHODSWe conducted a multicenter case-control study of cases with HCM and controls with hypertensive left ventricular hypertrophy. We performed plasma proteomics profiling of 1681 proteins. We performed a sparse partial least squares discriminant analysis to develop a proteomics-based discrimination model with data from 1 institution (ie, the training set). We tested the discriminative ability in independent samples from the other institution (ie, the test set). As an exploratory analysis, we executed pathway analysis of significantly dysregulated proteins. Pathways with false discovery rate <0.05 were declared positive. RESULTSThe study included 266 cases and 167 controls (n=308 in the training set; n=125 in the test set). Using the proteomics-based model derived from the training set, the area under the receiver operating characteristic curve was 0.89 (95% CI, 0.83-0.94) in the test set. Pathway analysis revealed that the Ras-MAPK (mitogen-activated protein kinase) pathway, along with its upstream and downstream pathways, was upregulated in HCM. Pathways involved in inflammation and fibrosis-for example, the TGF (transforming growth factor)-β pathway-were also upregulated. CONCLUSIONSThis study serves as the largest-scale investigation with the most comprehensive proteomics profiling in HCM, revealing circulating biomarkers and exhibiting both novel (eg, Ras-MAPK) and known (eg, TGF-β) pathways differentially regulated in HCM.</description><identifier>ISSN: 1941-3297</identifier><identifier>ISSN: 1941-3289</identifier><identifier>EISSN: 1941-3297</identifier><identifier>DOI: 10.1161/CIRCHEARTFAILURE.120.007849</identifier><identifier>PMID: 34192899</identifier><language>eng</language><publisher>Lippincott Williams & Wilkins</publisher><ispartof>Circulation. Heart failure, 2021-07, Vol.14 (7), p.e007849-e007849</ispartof><rights>Lippincott Williams & Wilkins</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4515-c9733e170934cfcb77382c23509ae69fc7999ad66ccfecda3995c37a9b6c4ca73</citedby><cites>FETCH-LOGICAL-c4515-c9733e170934cfcb77382c23509ae69fc7999ad66ccfecda3995c37a9b6c4ca73</cites><orcidid>0000-0002-3494-307X ; 0000-0002-5739-7999 ; 0000-0002-5805-9369 ; 0000-0002-1867-0526 ; 0000-0003-3931-4085 ; 0000-0002-8363-445X ; 0000-0002-3035-9386</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3687,27924,27925</link.rule.ids></links><search><creatorcontrib>Shimada, Yuichi J.</creatorcontrib><creatorcontrib>Raita, Yoshihiko</creatorcontrib><creatorcontrib>Liang, Lusha W.</creatorcontrib><creatorcontrib>Maurer, Mathew S.</creatorcontrib><creatorcontrib>Hasegawa, Kohei</creatorcontrib><creatorcontrib>Fifer, Michael A.</creatorcontrib><creatorcontrib>Reilly, Muredach P.</creatorcontrib><title>Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy</title><title>Circulation. Heart failure</title><description>BACKGROUNDHypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development of HCM. The objectives were to determine plasma protein biomarkers of HCM and to reveal molecular pathways differentially regulated in HCM. METHODSWe conducted a multicenter case-control study of cases with HCM and controls with hypertensive left ventricular hypertrophy. We performed plasma proteomics profiling of 1681 proteins. We performed a sparse partial least squares discriminant analysis to develop a proteomics-based discrimination model with data from 1 institution (ie, the training set). We tested the discriminative ability in independent samples from the other institution (ie, the test set). As an exploratory analysis, we executed pathway analysis of significantly dysregulated proteins. Pathways with false discovery rate <0.05 were declared positive. RESULTSThe study included 266 cases and 167 controls (n=308 in the training set; n=125 in the test set). Using the proteomics-based model derived from the training set, the area under the receiver operating characteristic curve was 0.89 (95% CI, 0.83-0.94) in the test set. Pathway analysis revealed that the Ras-MAPK (mitogen-activated protein kinase) pathway, along with its upstream and downstream pathways, was upregulated in HCM. Pathways involved in inflammation and fibrosis-for example, the TGF (transforming growth factor)-β pathway-were also upregulated. CONCLUSIONSThis study serves as the largest-scale investigation with the most comprehensive proteomics profiling in HCM, revealing circulating biomarkers and exhibiting both novel (eg, Ras-MAPK) and known (eg, TGF-β) pathways differentially regulated in HCM.</description><issn>1941-3297</issn><issn>1941-3289</issn><issn>1941-3297</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUV1r20AQFKGlSdP-B0Ff-iL3PnVeCgFXOLXB0GKS5-v5vIoukXTqneTgf98zDiXtw7LLzs7sspNlnyiZUVrSL9V6W62Wi-3d7WK9ud8uZ5SRGSFqLuAiu6IgaMEZqDev6svsfYyPhJRMSniXXXJBgc0BrrJfle-GgA320R0w_xn8iL5zNp7K2rWuf8i3eEDTxrxywU6tGU-9b853JjxhiLmv89VxwDAGPzTO5pUJ-4Qe_WDG5vghe1snMn58ydfZ_e3yrloVmx_f19ViU1ghqSwsKM6RKgJc2NrulOJzZhmXBAyWUFsFAGZfltbWaPeGA0jLlYFdaYU1il9nN2fdYdp1uLfYj8G0eggu3XnU3jj9L9K7Rj_4g54zYIyWSeDzi0DwvyeMo-5ctNi2pkc_Rc2kUJJT4DKNfj2P2uBjDFj_XUOJPnmk__dIJ4_02aPEFmf2s2_H9MCndnrGoJv047HRhHKuBIiCEUaJIoQUKYjkfwCKjZkc</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Shimada, Yuichi J.</creator><creator>Raita, Yoshihiko</creator><creator>Liang, Lusha W.</creator><creator>Maurer, Mathew S.</creator><creator>Hasegawa, Kohei</creator><creator>Fifer, Michael A.</creator><creator>Reilly, Muredach P.</creator><general>Lippincott Williams & Wilkins</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3494-307X</orcidid><orcidid>https://orcid.org/0000-0002-5739-7999</orcidid><orcidid>https://orcid.org/0000-0002-5805-9369</orcidid><orcidid>https://orcid.org/0000-0002-1867-0526</orcidid><orcidid>https://orcid.org/0000-0003-3931-4085</orcidid><orcidid>https://orcid.org/0000-0002-8363-445X</orcidid><orcidid>https://orcid.org/0000-0002-3035-9386</orcidid></search><sort><creationdate>20210701</creationdate><title>Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy</title><author>Shimada, Yuichi J. ; Raita, Yoshihiko ; Liang, Lusha W. ; Maurer, Mathew S. ; Hasegawa, Kohei ; Fifer, Michael A. ; Reilly, Muredach P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4515-c9733e170934cfcb77382c23509ae69fc7999ad66ccfecda3995c37a9b6c4ca73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimada, Yuichi J.</creatorcontrib><creatorcontrib>Raita, Yoshihiko</creatorcontrib><creatorcontrib>Liang, Lusha W.</creatorcontrib><creatorcontrib>Maurer, Mathew S.</creatorcontrib><creatorcontrib>Hasegawa, Kohei</creatorcontrib><creatorcontrib>Fifer, Michael A.</creatorcontrib><creatorcontrib>Reilly, Muredach P.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Circulation. Heart failure</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimada, Yuichi J.</au><au>Raita, Yoshihiko</au><au>Liang, Lusha W.</au><au>Maurer, Mathew S.</au><au>Hasegawa, Kohei</au><au>Fifer, Michael A.</au><au>Reilly, Muredach P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy</atitle><jtitle>Circulation. Heart failure</jtitle><date>2021-07-01</date><risdate>2021</risdate><volume>14</volume><issue>7</issue><spage>e007849</spage><epage>e007849</epage><pages>e007849-e007849</pages><issn>1941-3297</issn><issn>1941-3289</issn><eissn>1941-3297</eissn><abstract>BACKGROUNDHypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development of HCM. The objectives were to determine plasma protein biomarkers of HCM and to reveal molecular pathways differentially regulated in HCM. METHODSWe conducted a multicenter case-control study of cases with HCM and controls with hypertensive left ventricular hypertrophy. We performed plasma proteomics profiling of 1681 proteins. We performed a sparse partial least squares discriminant analysis to develop a proteomics-based discrimination model with data from 1 institution (ie, the training set). We tested the discriminative ability in independent samples from the other institution (ie, the test set). As an exploratory analysis, we executed pathway analysis of significantly dysregulated proteins. Pathways with false discovery rate <0.05 were declared positive. RESULTSThe study included 266 cases and 167 controls (n=308 in the training set; n=125 in the test set). Using the proteomics-based model derived from the training set, the area under the receiver operating characteristic curve was 0.89 (95% CI, 0.83-0.94) in the test set. Pathway analysis revealed that the Ras-MAPK (mitogen-activated protein kinase) pathway, along with its upstream and downstream pathways, was upregulated in HCM. Pathways involved in inflammation and fibrosis-for example, the TGF (transforming growth factor)-β pathway-were also upregulated. CONCLUSIONSThis study serves as the largest-scale investigation with the most comprehensive proteomics profiling in HCM, revealing circulating biomarkers and exhibiting both novel (eg, Ras-MAPK) and known (eg, TGF-β) pathways differentially regulated in HCM.</abstract><pub>Lippincott Williams & Wilkins</pub><pmid>34192899</pmid><doi>10.1161/CIRCHEARTFAILURE.120.007849</doi><orcidid>https://orcid.org/0000-0002-3494-307X</orcidid><orcidid>https://orcid.org/0000-0002-5739-7999</orcidid><orcidid>https://orcid.org/0000-0002-5805-9369</orcidid><orcidid>https://orcid.org/0000-0002-1867-0526</orcidid><orcidid>https://orcid.org/0000-0003-3931-4085</orcidid><orcidid>https://orcid.org/0000-0002-8363-445X</orcidid><orcidid>https://orcid.org/0000-0002-3035-9386</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-3297 |
| ispartof | Circulation. Heart failure, 2021-07, Vol.14 (7), p.e007849-e007849 |
| issn | 1941-3297 1941-3289 1941-3297 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8292216 |
| source | American Heart Association Journals; EZB-FREE-00999 freely available EZB journals |
| title | Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A40%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comprehensive%20Proteomics%20Profiling%20Reveals%20Circulating%20Biomarkers%20of%20Hypertrophic%20Cardiomyopathy&rft.jtitle=Circulation.%20Heart%20failure&rft.au=Shimada,%20Yuichi%20J.&rft.date=2021-07-01&rft.volume=14&rft.issue=7&rft.spage=e007849&rft.epage=e007849&rft.pages=e007849-e007849&rft.issn=1941-3297&rft.eissn=1941-3297&rft_id=info:doi/10.1161/CIRCHEARTFAILURE.120.007849&rft_dat=%3Cproquest_pubme%3E2547531935%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547531935&rft_id=info:pmid/34192899&rfr_iscdi=true |